Rare and clinically highly variable, Sarcoma is a type of cancer that originates from mesenchymal cells transformation. Sarcoma defines as the major tumors, such as bone, breast, skin, fats and soft tissues. One such rare type of soft tissue tumor is called as Angiosarcomas. This tumor begins to grow in the cells of a blood vessels and can occur in any part of body.    Angiosarcoma tumors involve rapidly proliferating cancerous cells originated from endothelial or mesenchymal sources and develop blood filled channels. Angiosarcoma harbors is the worst prognosis among all sarcoma subtypes.

Angiosarcomas treatment market classification

Depending on the instigation of tumor, Angiosarcomas are classified as hemagiosarcoma (begin in blood vessels) and lymphangiosarcome (tumor begins in lymph vessels). The major causes of the disease are unknown, however, lymphederma is considered as a key propeller of the disease condition. In addition to this, frequent and long term exposure of the radiation is also considered as an important cause.

The major symptoms include skin infections; however, the deeply situated tumors may not show any distinct symptom of the disease. The latter condition worsens the situation and may be a fatal one. The diagnostic procedures mainly include CT, MRI and PET scan. In addition, biopsy procedure has proved its effectiveness in the disease diagnosis. This disease has a very low incidence rate of 2-3 per million people and also occurs in patients of breast cancer who have undergone radiation therapy.

Angiosarcomas treatment market remedies

Angiosarcoma treatment requires medical attention from a multidisciplinary medical team and includes oncologists, surgeons and other medical team. The disease is treated primarily with surgical intervention. Chemotherapy is also used due to high risk of local relapse and distant metastatic disease. However, chemotherapy and radiation therapy are critical for treating Angiosarcomas before and after surgery. The most common chemotherapeutic drug for treating Angiosarcomas includes doxorubicin. However, combination therapy involving mesna, doxorubicin, and ifosfamide has also shown effectiveness against Angiosarcomas. There have been several attempts in last decade to develop drugs that target blood vessels growth stimulator VEGF and thereby cause shrinking of angiosarcomas. These drugs include bevacizumab, irinotecan, sildenafil, SU11248, BAY43-9006, and AMG706. Radiation therapy includes exposure of high power gamma and X-rays to irradiate the tumors.

Angiosarcomas treatment market research

In a recent research at University of North Carolina, researcher reported a monoclonal antibody targeted towards a protein known as SFRP2 found to inhibit growth of angiosarcoma. The study was initiated because SFRP2 acts as a potent stimulator of angiogenesis and it was therefore hypothesized that targeting SFRP2 could inhibit tumor growth. The study is still in very nascent stage and will enter into clinical trials provided the researchers obtain enough funding for their research.  The major drivers of the market include steadily increasing prevalence of the disease. Although the disease is considered as rare (less than 1 percent of the sarcoma diagnosed population), the prevalence is increasing steadily. This is anticipated to drive the market during forecast period 2014 – 2020. In addition, extensive R&D practices also fuels the market growth. A number of drugs, such as, AMG-386, sildenafil, and many others are under pipeline studies and expected to enter in the market in coming 5-10 years. A major restraint in developing specific drug for treating Angiosarcomas is the limited number of people on which the drug can be tested to confirm its safety and efficacy. Angiosarcomas are so rare accounting for only 1% of sarcomas which in turn account for only 1 percent of all kinds of cancer.

The major players operating in the global Angiosarcomas market include Pfizer, Inc., Genentech, Inc., Bayer Healthcare, Janssen Products, LP, Sanofi S.A., and Amgen, Inc.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

REQUEST CUSTOMIZATION

Angiosarcomas Treatment Market

Pre Book